Details of the Drug Combination

General Information of Drug Combination (ID: DC6SABW)

Drug Combination Name

Picoplatin Arfolitixorin

Indication

Disease Entry	Status	REF
High grade ovarian serous adenocarcinoma	Investigative	[1]

Component Drugs

Picoplatin DM0PIY6

Arfolitixorin DMIXMYK

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: OVCAR-4

Zero Interaction Potency (ZIP) Score: 2.56

Bliss Independence Score: 5.37

Loewe Additivity Score: 1.85

LHighest Single Agent (HSA) Score: 1.88

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Mixed endometrioid and clear cell carcinoma	DC4KZR8	IGROV1	Investigative	[1]
------------------------------------------------------------------------------------

References

1	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2	ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.